| Literature DB >> 20113895 |
Jeffrey E Rubnitz1, Brenda Gibson, Franklin O Smith.
Abstract
Acute myeloid leukemia (AML) is a heterogeneous group of leukemias that result from clonal transformation of hematopoietic precursors through the acquisition of chromosomal rearrangements and multiple gene mutations. As a result of highly collaborative clinical research by pediatric cooperative cancer groups worldwide, disease-free survival has improved significantly during the past 3 decades. Further improvements in outcomes of children who have AML probably will reflect continued progress in understanding the biology of AML and the concomitant development of new molecularly targeted agents for use in combination with conventional chemotherapy drugs. Copyright (c) 2010 Elsevier Inc. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20113895 DOI： 10.1016/j.hoc.2009.11.008
Source DB: PubMed Journal: Hematol Oncol Clin North Am ISSN： 0889-8588 Impact factor: 3.722